Boehringer’s Zongertinib Wins China Conditional Approval as ASCO Data Show Patient Benefit and Broader Activity

Early trial results and patient‑reported outcomes suggest the oral HER2 inhibitor improves symptoms and works in other HER2‑driven cancers, but confirmatory Phase III studies must verify durability and safety.

Overview

China’s NMPA granted conditional approval for zongertinib as a first‑line treatment for unresectable or metastatic NSCLC with HER2 tyrosine kinase domain mutations based on a reported 75.7% objective response rate.
New patient‑reported outcomes from the Phase Ib Beamion LUNG‑1 program showed patients treated with zongertinib reported faster improvements in physical function and reduced lung cancer symptom burden versus baseline.
Early clinical signals also appeared in other HER2‑driven tumors, including a pooled analysis in HER2‑positive metastatic colorectal cancer that showed a 42% confirmed response rate and 95% disease control rate.
Updated Phase I DAREON‑8 data for obrixtamig, a DLL3/CD3 T‑cell engager used with chemo and atezolizumab in first‑line extensive‑stage SCLC, showed a 73% confirmed response rate and 91% disease control but median response duration and PFS remain immature.
Boehringer is advancing multiple Phase III and confirmatory trials for both programs, so regulators and clinicians will be watching durability, long‑term safety signals such as liver and cardiac AEs for zongertinib and cytokine release syndrome for obrixtamig.